ArticleCancers2025

Adjuvant Metronomic Chemotherapy After Surgery in pT1-T2 N0 M0 HER2-Positive and ER/PR-Positive Breast Cancer Plus Targeted Therapy, Anti-Hormonal Therapy, and Radiotherapy, with or Without Immunotherapy: A New Operational Proposal.

Luca RoncatiPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.